Wikisage, the free encyclopedia of the second generation, is digital heritage

Molnupiravir: Difference between revisions

From Wikisage
Jump to navigation Jump to search
No edit summary
 
(One intermediate revision by the same user not shown)
Line 6: Line 6:
===EIDD 2801===
===EIDD 2801===
[https://www.nature.com/articles/s41564-020-00835-2 Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets]
[https://www.nature.com/articles/s41564-020-00835-2 Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets]
<references/>
==Source==
==Source==
[https://enwiki.miraheze.org/w/index.php?title=Molnupiravir&oldid=2390 enWiki(Miraheze)]
[https://enwiki.miraheze.org/w/index.php?title=Molnupiravir&oldid=2390 enWiki(Miraheze)]


[[d:Q96376832]]
 
{{Wikidata|Q96376832}}
 
{{refs}}

Latest revision as of 14:20, 27 January 2021

Molnupiravir (development codes EIDD-2801 and MK-4482) is an investigational antiviral drug for oral administration for the treatment of influenza. It is an N4-hydroxycytidine-donating prodrug, a nucleoside derivative known to be mutagenic that acts against RNA viruses by introducing errors in RNA replication by the viral RNA-dependent RNA polymerase. It also has some activity against coronaviruses such as SARS-CoV, MERS-CoV and SARS-CoV-25, responsible for SARS, MERS and COVID-19 respectively. It was developed at Emory University in Atlanta, Georgia, before being acquired by Ridgeback Biotherapeutics in Miami, Florida, which has partnered with Merck & Co. for further development. [1]

External Links

Coronavirus RNA Proofreading Molecular basis and therapeutic target

EIDD 2801

Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets

Source

enWiki(Miraheze)


Q96376832 at Wikidata  Interwiki via Wikidata


References

References: